Irbinitinib

Research use only, not for human use.

Irbinitinib(ARRY-380; ONT-380) is a potent and selective HER2 inhibitor (IC50: 8 nM).

Tucatinib, also known as Irbinitinib, ARRY-380 and ONT-380, is a n orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. ErbB-2 inhibitor ARRY-380 selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.

——

Animal Model:Female nude mice.Dosage:200 mg/kg/d.Administration:PO, daily. Result:Exhibited anti-tumor activity and benefited survival.

ARRY380 | ARRY 380 | ONT-380. Irbinitinib | Tucatinib

Neuroscience

GluR

EGFR| HER2/ErbB2| p95 HER2

Cancer

——

937263-43-9

480.52

C26H24N8O2

>98% (HPLC)

DMSO : 50 mg/mL. 104.05 mM;

Cc1c(ccc(c1)Nc1ncnc2c1cc(cc2)NC1=NC(CO1)(C)C)Oc1cc2ncnn2cc1

N6-(4,4-Dimethyl-4,5-dihydrooxazol-2-yl)-N4-(3-methyl-4-((1,2,4)triazolo(1,5-a)pyridin-7-yloxy)phenyl)quinazoline-4,6-diamine

(-20℃)

With Ice Pack

≥ 2 years